ThinkGen provides customized market research solutions for healthcare companies. The foundation for our success is based on us knowing the science behind the research, asking the right questions, and finding and reporting relevant insights. We view customer insights through the lens of our combined years of both in-depth marketing research as well as pharmaceutical marketing experience to deliver actionable insights for you, our client. In short, we deliver outcomes worthy of admiration. ThinkGen is a proactive partner, using effective research methods, while helping to push projects forward.

Patient Health Perspectives, LLC creates innovative programs and services that enable biotechnology and pharmaceutical companies to take "patient centricity"​ to the next level by infusing the patient and caregiver perspective across the continuum of drug development and commercialization. Our people, proven processes, and technology-based solutions enable novel, impactful, and compliant interactions between industry and the individual consumers they serve and support. From spokesperson identification and training, to patient advisory councils, to patient-to-patient support programs we help clients navigate the changing consumer and regulatory environment and put patients at the center of everything they do.

Led the development and implementation of strategy for high-growth specialty pharmaceutical company. STRATEGIC PLANNING & GO-TO-MARKET STRATEGY:• Established strategic priorities, created the roadmap for implementation of key initiatives, and ensured alignment of the organization’s resources and capabilities to the overall strategic plan. • Defined the opportunity space for AMAG's maternal health division. Identified, assessed, and advanced key opportunities (internal and external) with potential for positive impact on product growth and profitability through near- and longer-term time horizons. CROSS-FUNCTIONAL LEADERSHIP:• Established strategic frameworks and coordinated with functional areas to identify specific solutions required to deliver against identified customer needs, business challenges, and Company objectives. • Ensured alignment of product strategy to the Company’s overall vision and goals; aligned functional teams across the organization with product strategy.FOCUSED EXECUTION:• Ensured the progression and integration of key initiatives; monitored implementation of strategic initiatives and course corrected as needed. • Ensured organizational structure, resources, and capabilities appropriately supported implementation of the strategic plan; drove change to address gaps as needed. • Assisted functional areas with key strategic projects, problem-solved with and counseled leaders, and provided guidance to organization around problem structuring, action planning, and recommendation synthesis.

Partnered with clients to develop and implement market-winning brand and therapeutic area strategies.• Marketing Strategy: Provided customer insights generation, strategic planning, and development services for clients in women’s health, virology, and pulmonology. • Corporate Rebuilding and Rebranding: Led development and execution of corporate rebranding plan for Ther-Rx Corporation; launched Lumara Health in May 2014. Company sold to AMAG Pharmaceuticals in $1B deal in Sep. 2014.• Communications Strategy and Execution: Established overall reputation management strategy for Lumara Health; served as company spokeswoman and head of external relations. • Public Affairs and Advocacy: Assisted clients in developing and implementing stakeholder engagement and policy initiatives, including successful passage of federal legislation in 2014.

• New Product Launch Planning. Championed and led formal cross-functional launch readiness initiative for Makena, a specialty injectable (orphan drug) approved by FDA in Feb. 2011.• Crisis Management. Part of core leadership team responsible for managing strategic direction, materials development, and execution in response to Makena pricing crisis. Developed and executed communications plan for Company's Chapter 11 restructuring filing.• Advocacy. Drove advocacy for Makena among stakeholders. Briefed Senate HELP/Finance Committee staff, Congressional staff, and government agencies on Makena. As a result, statements supporting prescribing of Makena were issued by two healthcare professional societies in Oct. 2011, and by FDA and the Centers for Medicare & Medicaid Services in Jun. 2012.• Sales Force Training and Competency Development. Led sales force transition from a traditional to an account-based selling model in partnership with Vice President of Sales. • Managerial Experience. Head of marketing team for Ther-Rx. Responsible for two direct reports and strategic oversight of brand campaigns to drive sales of Ther-Rx’s women’s health portfolio.• Organizational Development. Provided strategic guidance for numerous corporate recovery initiatives, including options for prenatal vitamin franchise; corporate rebranding; formal mentoring program; and five-year plan. • Recognition. Winner of CEO's Merit Award in 2011. Promoted to Senior Director, February 2012. Appointed by CEO to Executive Committee, March 2012.

• Head of marketing for Ther-Rx Corporation's Advanced Prescription Nutritionals franchise, the leading line of prescription prenatal vitamins in the U.S. Responsible for strategic development and operational execution of marketing initiatives for product portfolio representing 40% of company's net revenues.• Re-energized team of three direct reports and led launch of enhanced formulation for PrimaCare ONE (America's #1 prescribed prenatal vitamin) within first 60 days at Ther-Rx, elevating senior leadership team’s confidence in franchise.• Exceeded management expectations by delivering a revamped and executable fiscal year 2010 strategic plan for franchise within first 90 days at Ther-Rx.• Retained as part of leadership team despite mass layoff that affected two-thirds of employees in February 2009.

• Elevated recognition of Abbott as a responsible leader in pain management by developing comprehensive pain care advocacy strategy and driving execution of collaborative programs with national thought leaders, patient advocacy groups, and anti-abuse organizations.• Led cross-functional team and four direct reports to create and implement strategic and tactical launch plan for Vicodin CR. Areas of responsibility include advocacy, medical education, health economics outcomes research, publications, public relations, and appropriate use initiatives.• Initiated and fostered a first-of-its kind alliance between a major pharmaceutical company and The Partnership for a Drug-Free America, the foremost authority on drug abuse in the U.S. Led cross-functional team in development and launch of "Not in my House," a major national anti-teen prescription drug abuse campaign.• Part of core leadership team responsible for headcount expansion and hiring of 10 product managers beginning in Nov. 2006.• Recognized as Pain Care franchise's top performer in 2006 and 2007.

• Led marketing launch campaign for FIELD study, TriCor's first cardiovascular outcomes trial. Developed launch strategy, key messaging, and tactical plan; ensured timely and impactful dissemination of study results to physicians through educational and promotional launch initiatives.• Developed and executed medical education plan for Dyslipidemia franchise. Created tactical framework, added innovative programs, expanded reach, integrated key messages, and managed multiple medical education providers to effectively and efficiently drive rollout of 1.1 million medical education touchpoints in 2005.• Led launch of Fournier co-promotion sales force for TriCor. Partnered with key support teams to deploy co-promotion sales representatives; managed day-to-day alliance activities to maximize TriCor's sales.

• Senior Market Research Analyst, Immunology Franchise, 2003-2004. • Urology Sales Specialist, 2002-2003.

• Designed first-to-market entry strategy for plastic beer bottle market segment. Strategy was implemented successfully, increasing resin sales by 20 MM lbs/year and resulting in approval of $2 MM capital expenditure to implement new manufacturing process.• Developed new process to manufacture recycle-content polymer. Analyzed process economics and developed product performance data, resulting in approval of $1.5 MM capital expenditure for recycle capability.

• Invented and patented three commercially-successful technologies, resulting in leading-performance plastic resin on the market.